Acarbose is again on the stage.

Area of Science:

• Endocrinology
• Metabolic Diseases
• Pharmacology

Background:

• Acarbose has been a type 2 diabetes treatment for three decades, primarily managing postprandial hyperglycemia by inhibiting intestinal carbohydrate digestion.
• Its usage has declined with the rise of incretin-based therapies over the past 10-15 years.
• Emerging research indicates acarbose may promote weight loss by elevating glucagon-like peptide 1 (GLP-1) levels.

Discussion:

• The dual action of acarbose on GLP-1 modulation and its established efficacy in diabetes management warrants a re-evaluation of its therapeutic role.
• Cardiovascular protective effects, alongside metabolic benefits, position acarbose as a potentially valuable agent in comprehensive diabetes care.
• The mechanism involves inhibiting alpha-glucosidase enzymes, slowing carbohydrate absorption and impacting incretin hormone release.

Key Insights:

• Acarbose demonstrates a positive impact on glucagon-like peptide 1 (GLP-1) secretion.
• Evidence suggests acarbose confers cardiovascular protection in patients with type 2 diabetes.
• The drug's efficacy in managing postprandial hyperglycemia remains a key benefit.

Outlook:

• Acarbose could be reconsidered as a first-line antidiabetic agent, similar to its status in the 1990s.
• Further clinical trials are recommended to confirm its cardiovascular benefits and weight-loss effects.
• Integrating acarbose into modern diabetes treatment algorithms may offer a cost-effective and beneficial therapeutic option.